1. First‐line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations
   Noriaki Ito et al, 2022, Thoracic Cancer CrossRef
2. The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC
   Fen Wang et al, 2022, Journal of Thoracic Oncology CrossRef
3. Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation–Case Report and A Literature Review
   Anna Rekowska et al, 2022, Current Oncology CrossRef
4. Detection and Significance of Cell-Free DNA Mutation in Pleural Effusion in Patients with Advanced NSCLC
   Man Qiao et al, 2022, Emergency Medicine International CrossRef
5. Cosuppression of NF-κB and AICDA Overcomes Acquired EGFR-TKI Resistance in Non-Small Cell Lung Cancer
   Min-Kyung Yeo et al, 2022, Cancers CrossRef
6. Metal-Tyrosine Kinase Inhibitors: Targeted metal-drug conjugates
   Darren F. Beirne et al, 2022, Coordination Chemistry Reviews CrossRef
7. Emerging strategies to overcome resistance to third-generation EGFR inhibitors
   Kunyu Shi et al, 2022, J Hematol Oncol CrossRef
8. The role of mesenchymal-epithelial transition factor (c-MET) in cancer development and treatments
   Yuxuan Xie, 2022, HSET CrossRef
9. Significant metabolic alterations in non-small cell lung cancer patients by epidermal growth factor receptor-targeted therapy and PD-1/PD-L1 immunotherapy
   Chen Yan et al, 2022, Front. Pharmacol. CrossRef
10. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials
    Wusheng Deng et al, 2022, BMJ Open CrossRef
11. An overview of epithelial growth factor receptor (EGFR) inhibitors in cancer therapy
    Khalid Saad Alharbi et al, 2022, Chemico-Biological Interactions CrossRef
12. Genetic alterations shaping tumor response to anti-EGFR therapies
    Javier Vaquero et al, 2022, Drug Resistance Updates CrossRef
13. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
    Yang Yang et al, 2022, Sig Transduct Target Ther CrossRef
14. Proteomic and Phosphoproteomic Analyses Reveal the Oncogenic Role of PTK7-NDRG1 Axis in Non-small-cell Lung Cancer Cell Resistance to AZD9291
    Zhen Wang et al, 2022, ACS Chem. Biol. CrossRef
15. PLEKHH2 binds β-arrestin1 through its FERM domain, activates FAK/PI3K/AKT phosphorylation, and promotes the malignant phenotype of non-small cell lung cancer
    Rui Wang et al, 2022, Cell Death Dis CrossRef
16. Aumolertinib challenge as an optional treatment in advanced non small‑cell lung cancer after osimertinib failure with epidermal growth factor receptor‑sensitive mutation: A case series
    Xinjing Ding et al, 2022, Oncol Lett CrossRef
17. Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)
    Ruizhu Sun et al, 2022, Oncol Lett CrossRef
18. null
    Bengisu Dayanc et al, 2022 CrossRef
19. Case Report: A patient with the rare third-generation TKI-resistant mutation EGFR L718Q who responded to afatinib plus cetuximab combination therapy
    Guoqing Zhang et al, 2022, Front. Oncol. CrossRef
20. Role of protein phosphorylation in cell signaling, disease, and the intervention therapy
    Kun Pang et al, 2022, MedComm CrossRef
21. Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases
    Hao Liu et al, 2022, Front. Oncol. CrossRef
22. Feiyanning formula modulates the molecular mechanism of osimertinib resistance in lung cancer by regulating the Wnt/β-catenin pathway
    Shuliu Sang et al, 2022, Front. Pharmacol. CrossRef
23. Adjuvant Immunotherapy in Patients with Early-Stage Non-small Cell Lung Cancer and Future Directions
    Stephanie PL Saw et al, 2022, Curr. Treat. Options in Oncol. CrossRef
24. Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model
    Nadeem Moghal et al, 2022, Journal of Thoracic Oncology CrossRef
25. The Silkworm Carboxypeptidase Inhibitor Prevents Gastric Cancer Cells’ Proliferation through the EGF/EGFR Signaling Pathway
    Junhong Ye et al, 2023, IJMS CrossRef
26. First-, Second-, and Third-Generation Radiolabeled Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Positron Emission Tomography: State of the Art, a Systematic Review
    Marko Magdi Abdou Sidrak et al, 2023, Cancer Biotherapy and Radiopharmaceuticals CrossRef
27. MMP11 is associated with the immune response and immune microenvironment in EGFR-mutant lung adenocarcinoma
    Lu Bai et al, 2023, Front. Oncol. CrossRef
28. A novel intergenic region (chr2: 30,193,816)-ALK fusion shows sensitivity to Alectinib in lung adenocarcinoma
    Ting Wang et al, 2023, BMC Pulm Med CrossRef
29. Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy
    Michael R. Sayer et al, 2023, Front. Oncol. CrossRef
30. Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes
    Weixin Zhao et al, 2023, BMC Med CrossRef
31. Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions
    Jia Zhong et al, 2023, Front. Med. CrossRef
32. The Usefulness of Nanotechnology in Improving the Prognosis of Lung Cancer
    Gabriela Bordeianu et al, 2023, Biomedicines CrossRef
33. A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine
    Martin Sattler et al, 2023, JCM CrossRef
34. Advances in Targeted Therapy Against Driver Mutations and Epigenetic Alterations in Non-Small Cell Lung Cancer
    Jiajian Shi et al, 2022 CrossRef
35. Treatment Patterns, Testing Practices, and Outcomes in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer in Poland: A Descriptive Analysis of National, Multicenter, Real-World Data from the REFLECT Study
    Adam Pluzanski et al, 2023, Cancers CrossRef
36. Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review
    Nunzio Digiacomo et al, 2023, Current Oncology CrossRef
37. Targeting Harvey rat sarcoma viral oncogene homolog in head and neck cancer: how to move forward?
    Hédi Ben Yahia et al, 2023 CrossRef
38. Single-cell gene set enrichment analysis and transfer learning for functional annotation of scRNA-seq data
    Melania Franchini et al, 2023 CrossRef
39. Antitumor activity and mechanisms of dual EGFR/DNA-targeting strategy for the treatment of lung cancer with EGFRL858R/T790M mutation
    Lumei Dai et al, 2023, Bioorganic Chemistry CrossRef
40. A homologous and molecular dual-targeted biomimetic nanocarrier for EGFR-related non-small cell lung cancer therapy
    Bin Xu et al, 2023, Bioactive Materials CrossRef
41. The topoisomerase inhibitor CPT-11 prevents the growth and metastasis of lung cancer cells in nude mice by inhibiting EGFR/MAPK signaling pathway
    Yingqiu Yin et al, 2023, Heliyon CrossRef
42. Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidine and thieno[2,3-d]pyrimidine derivatives as novel EGFRL858R/T790M inhibitors
    Jianfang Fu et al, 2023, Journal of Enzyme Inhibition and Medicinal Chemistry CrossRef
43. Interpretable deep learning survival predictive tool for small cell lung cancer
    Dongrui Zhang et al, 2023, Front. Oncol. CrossRef
44. Determination of binding affinities between nuclear localization signal peptides of irradiated EGFR and KPNA using single‐molecule pull‐down assay and development of assay system for inhibitor screening
    Jiwon Oh et al, 2023, Bulletin Korean Chem Soc CrossRef
45. Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?
    Sushanta Halder et al, 2023, Expert Opinion on Therapeutic Targets CrossRef
46. Multi‐target angiogenesis inhibitor combined with PD‐1 inhibitors may benefit advanced non‐small cell lung cancer patients in late line after failure of EGFR‐TKI therapy
    Lian Yu et al, 2023, Intl Journal of Cancer CrossRef
47. Symptoms and Experiences with Small Cell Lung Cancer: A Mixed Methods Study of Patients and Caregivers
    D. Gwyn Bebb et al, 2023, Pulm Ther CrossRef
48. Arsenic Inhibits Proliferation and Induces Autophagy of Tumor Cells in Pleural Effusion of Patients with Non-Small Cell Lung Cancer Expressing EGFR with or without Mutations via PI3K/AKT/mTOR Pathway
    Jianhua Mao et al, 2023, Biomedicines CrossRef
49. Long-lasting benefit on multimodal treatment combining osimertinib and stereotaxic radiotherapy for metastatic non-small cell lung cancer with the EGFR exon 20 insertion 773-774 HVdelinsLM: a case report
    Aurélie Louvet et al, 2023, Front. Oncol. CrossRef
50. Role of pelitinib in the regulation of migration and invasion of hepatocellular carcinoma cells via inhibition of Twist1
    Sewoong Lee et al, 2023, BMC Cancer CrossRef